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Private aspects of heterologous immunity
 
Barbara Rehermann and Eui-Cheol Shin
 
Clinical manifestations of viral infections are highly variable, both in type and 
severity, among individual patients. Differences in host genetics and in dose 
and route of infection contribute to this variability but do not fully explain it. 
New studies now show that each subject’s history of past infections 
individualizes the memory T cell pool. Private T cell receptor specificities 
of these preexisting memory T cell populations influence both disease severity 
and outcome of subsequent, unrelated virus infections.
 
Heterologous immunity is the term used
to describe the phenomenon by which
memory T cells that were generated dur-
ing an earlier infection are reactivated in
response to a second, unrelated infection.
This phenomenon was originally identi-
fied and characterized in a series of well-
controlled studies of viral infections in
mice (1–4). In this issue, a study by
Urbani et al. illustrates the potential sig-
nificance of heterologous immunity in
the pathogenesis of human viral infec-
tions (5). The authors studied hepatitis C
virus (HCV) infection, a disease that
affects  more than 170 million people
worldwide. Typically, the onset of HCV
infection is asymptomatic, and persistent
infection develops despite the presence
of a CD8 T cell response (6, 7). Urbani
et al. describe two patients with a very
rare fulminant onset of HCV infection
(5). Both patients displayed an unusual
CD8 T cell response that was unprece-
dented in its strength and narrow focus.
About 36% and 12% of all peripheral
blood CD8 T cells from these respective
patients targeted a single epitope within
the HCV nonstructural protein 3 (NS3)
and also cross-reactively recognized an
influenza A virus neuraminidase epitope
with close sequence similarity (5, 8). In
contrast, patients with nonfulminant on-
set of HCV infection displayed a broader,
multispecific CD8 T cell response of
lower magnitude (5–7, 9). The authors
concluded that exposure to influenza A
virus, as confirmed by cellular immune
responses against a second influenza A
virus epitope, preconditioned the CD8
T cell response to HCV and focused it
on a single cross-reactive epitope. The
result was severe immunopathology. The
notion of cross-reactivity was supported
by the demonstration that only those T
cells that bound HCV NS3 epitope–
MHC  tetramers produced interferon-
 
 
 
and increased cell surface expression of
the degranulation marker CD107a in
response to stimulation with the cross-
reactive  influenza A virus epitope. In
contrast, no response was observed upon
stimulation with an unrelated, noncross-
reactive influenza A virus epitope. The
cross-reactive nature of the response was
further confirmed by the demonstration
that those T cells that did not bind HCV
NS3 epitope–MHC tetramers did not
respond to stimulation with the cross-
reactive influenza A virus epitope.
Although the study did not provide
direct evidence that preexisting influ-
enza A virus–specific memory T cells
were indeed the source of the rapid,
vigorous, and narrowly focused HCV-
specific T cell response, this is a plausible
scenario for two reasons. HCV–cross-
reactive T cells can be induced by influ-
enza A virus infection of HLA-transgenic
mice (8), and HCV/influenza cross-reac-
tive  cells have also been described in
healthy blood donors, who are not
HCV infected and have no history of
HCV infection (8).
 
Factors determining cross-reactive 
immune responses
 
Two factors that determine the fre-
quency and extent of T cell cross-reac-
tivity are the likelihood of exposure to
a given virus and the sequence variability
of that virus. Influenza A virus infection
is one of the most common viral infec-
tions in humans. Variant strains of in-
fluenza are abundant, and reexposure
to the virus is common. If it can be as-
sumed that most HCV-infected people
have been infected previously with in-
fluenza A virus, why isn’t cross-reactivity
and severe immunopathology a more
common feature of HCV infection? In
fact, despite the high prevalence of in-
fluenza A virus infection, fulminant
acute hepatitis C is a very rare event
(10, 11). This may be due to several
factors. First, the HLA haplotype of the
patient is important. In the study by
Urbani et al., the cross-reactivity be-
tween the HCV NS3 epitope and the
influenza A virus neuraminidase epitope
was confined to HLA-A2–positive pa-
tients, as both epitopes are HLA-A2 re-
stricted (5, 8). Second, the sequence
diversity of HCV genomes that coexist
in each patient and the high mutation
rate of HCV may allow the virus to es-
cape from the T cell response and pre-
vent the reactivation of cross-reactive
T cells and the induction of immuno-
pathology. In the case of the HCV
NS3 epitope, mutations have been
identified both within and outside the
epitope (12, 13). Mutations within the
epitope may generate a T cell receptor
antagonist (12), and a mutation in its
COOH-terminal flanking sequence has
been shown to affect proteasomal pro-
cessing of the epitope and to reduce the
induction of epitope-specific T cells
(13). If the infecting virus displays these
mutations in an HLA-A2–positive pa-
tient, the altered HCV NS3 sequence
may not sufficiently activate preexisting
cross-reactive memory T cells. These
factors are difficult to assess in human
studies because patients typically seek
medical attention late after the actual
infection or not at all, making it impossi-
ble to determine the sequence of the
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original, infecting virus and to define
the patient’s early immune response.
An additional layer of complexity is
described in the elegant study of Kim et
al. in the previous issue of the 
 
JEM
 
 (14).
Using a murine model of sequential
lymphocytic choriomeningitis (LCMV)
and vaccinia virus (VV) infections, the
authors report differences in T cell
cross-reactivity even among mice of
identical genetic background that were
infected with identical viruses. When
mice were infected with LCMV, they
displayed similar hierarchies in the epi-
topes recognized but differed in their
TCR usage. These differences in TCR
CDR3 sequences determine the private
specificity of epitope-specific T cell
responses. When genetically identical,
LCMV-immune mice were then chal-
lenged with the unrelated VV, the pat-
tern of cross-reactivity varied between
mice. In contrast, when memory CD8
T cells from a single LCMV-immune
mouse were adoptively transferred into
several recipient mice, each of the recip-
ient mice mounted nearly identical re-
sponses to the subsequent VV infection.
The CD8 T cell response to VV chal-
lenge was influenced by preexisting
cross-reactive memory CD8 T cells as
demonstrated by simultaneous staining
of CD8 T cells with an MHC tetramer
that presents the LCMV epitope and a
second MHC tetramer that presents the
cross-reactive VV epitope. These results
demonstrate that private specificities of
preexisting memory CD8 T cell re-
sponses control the pattern of cross-
reactivity upon secondary infection
with unrelated viruses.
 
Features and consequences of 
heterologous immunity
 
Heterologous immunity differs from
classic homologous immunity in sev-
eral key aspects (Table I). As demon-
strated in mouse studies, heterologous
immunity can have beneficial and
harmful effects (Table II). It has, for
example, been shown to confer partial
protection against viral infections that
are otherwise lethal (4), but can also be
associated with more severe immuno-
pathology, especially in the absence of
a rapid, neutralizing antibody response
(1, 4). Furthermore, the absence of re-
ciprocal protection is remarkable. For
example, whereas LCMV-immune
mice display protective immunity
upon VV challenge, the reverse se-
quence of infections does not confer
protective immunity upon LCMV
challenge (4).
In the human study by Urbani et
al., both patients with cross-reactive T
cells developed persistent HCV infec-
tion despite vigorous HCV-specific T
cell responses and severe, presumably
immune-mediated, liver injury (5).
Since spontaneous recovery from and
protective immunity against HCV in-
fection (6, 15–18) are commonly asso-
ciated with vigorous HCV-specific T
cell responses, why was the vigorous T
cell response of these two patients un-
able to clear the infection? A similar ex-
ample for viral persistence despite vig-
orous, cross-reactive T cell responses
has been described recently for dengue
virus infection (19). After clearance of
primary dengue viral infection, subse-
quent infection with different dengue
serotypes results in hemorrhagic fever
without efficient viral control. Al-
though dengue virus serotoypes are not
completely unrelated, they are suffi-
ciently different in that they do not in-
duce a neutralizing antibody response.
But cross-reactive CD8 T cells do de-
velop and have been implicated in caus-
ing severe immunopathology without
efficient viral control (19).
A key characteristic of heterologous
immunity that may account for this in-
ability to clear the secondary infection
 
Table I.
 
Features of heterologous immunity compared to classic (homologous) immunity
 
Heterologous immunity Classic (homologous) immunity
 
Definition
 
Infecting virus unrelated to 
a previously encountered virus
Infecting virus identical to 
a previously encountered virus
 
Clinical course
 
Outcome  Clearance or persistence depending on 
the frequency and nature of cross-reactive T cells
Clearance
Immunopathology Can be severe  Attenuated compared to primary 
infection with the same virus
 
Antibodies
 
Neutralizing antibodies Absent Often present 
 
CD8 T cells
 
Kinetics  Early lymphopenia due to cytokine-induced apoptosis  Less lymphopenia due to effective
control of the challenge virus
Specificity Crossreactive, but not necessarily reciprocal Same epitopes 
Hierarchy Altered, as crossreactivity is often 
directed towards subdominant epitopes
Maintained from primary infection
Breadth Narrow, few epitopes Broad, many epitopes
TCR repertoire Restricted  Diverse 
TCR affinity Can be low  High
 
CD4 T cells
 
May confer crossreactivity, 
but its implications are not yet defined
Essential part of immunity
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is the altered epitope hierarchy and of-
ten narrow focus of the cross-reactive
T cell response (Table I). In both
patients with fulminant hepatitis C,
HCV-specific CD8 T cell responses
were narrowly focused on the cross-
reactive epitope (5), whereas other
patients with less symptomatic or
completely asymptomatic clinical pre-
sentation displayed a broader immune
response (5–7, 9). This deviated hierar-
chy was likely due to the preferential
expansion of cross-reactive memory
T cells, which have a low activation
threshold and may outpace the priming
of naive T cells. Furthermore, cross-
reactive memory T cells often display a
low affinity TCR (Table I), and low
affinity TCR stimulation may elicit
different effector functions compared
with full TCR stimulation (20, 21).
Cytotoxicity, a key function in immu-
nopathology, has been described as re-
quiring only weak TCR signals. Thus,
heterologous immunity may result in
epitope-specific T cells with an altered
effector profile, which together with
their narrow focus may cause immuno-
pathology and the inability to clear the
secondary virus.
Functionally altered CD4 T cell re-
sponses may also contribute to immu-
nopathology and incomplete protec-
tion under conditions of heterologous
immunity. An important role of CD4
T cells has been indicated in murine
studies, in which adoptive transfer of
both CD8 and CD4 subsets from
LCMV-immune mice into naive mice
resulted in heterologous immunity
upon subsequent infections with either
Pichinde virus or VV (1, 2). However,
the function of heterologous CD4 T
cell immunity has not been character-
ized so far and may clarify this point.
Alternatively, it is also possible that
cross-reactive CD4 T cells are com-
pletely absent and that the rapid expan-
sion of cross-reactive memory CD8 T
cells may outpace the induction of
new, primary CD4 T cells. This may
be especially detrimental for the out-
come of HCV infection, because CD4
T cell responses are associated with
HCV clearance (22), loss of CD4 T cell
responses results in HCV recurrence
(23), and in vivo depletion of CD4 T
cells from HCV-immune chimpanzees
abrogates protection upon subsequent
HCV rechallenge (24).
 
Conclusion
 
The discovery and further analysis of
heterologous immunity has simulta-
neously simplified and complicated our
understanding of infectious diseases. As
described in mouse models of virus in-
fection, cross-reactivity and heterolo-
gous immunity are an intrinsic part of
T cell biology and not incidental events
(4). These studies have provided clini-
cal investigators with an immunologi-
cal explanation for the observation that
memory T cells against specific viral
epitopes are often observed in healthy
subjects who lack any evidence of cur-
rent or past infection with that virus
(8). They have also provided a possible
explanation for the development of ex-
treme immunopathology in some viral
infections, as described in this issue (5).
 
Table II.
 
Examples of beneficial and harmful effects of heterologous immunity
 
First virus Second virus Outcome Reference
 
Beneficial effects
 
Mouse studies
LCMV Pichinde virus  Reduced Pichinde virus titer (1)
LCMV VV Reduced VV titer, 
increased survival upon
otherwise lethal VV dose
(1)
Pichinde virus VV Reduced VV titer (1)
Murine cytomegalovirus  LCMV Reduced LCMV titer (1)
Murine cytomegalovirus  VV Reduced VV titer (1)
Influenza virus VV Reduced VV titer (3)
Influenza virus RSV  Protection against weight loss, 
illness and lung eosinophilia 
in G-primed RSV-infected mice
(28)
 
Harmful effects
 
Mouse studies
LCMV VV (intraperitoneal infection) Acute fatty necrosis
LCMV VV (intranasal infection) Bronchiolitis obliterans (2)
LCMV RSV Increased RSV titer (29)
Influenza virus LCMV Increased LCMV titer, 
enhanced mononuclear infiltrate
(3)
Influenza virus Murine cytomegalovirus  Increased MCMV titer, 
enhanced mononuclear infiltrate
(3)
Human studies
Influenza virus HCV Fulminant hepatitis (5)
 
RSV, respiratory syncytial virus.
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In the future, studies on cross-reactivity
and heterologous immunity may be
important to understand why infections
with certain viruses such as measles,
mumps, varizella zoster, and Epstein-
Barr virus run a more severe course if
acquired during late adulthood than
during early childhood and why certain
infections appear to predispose to the
development of autoimmune diseases
(25) or to the rejection of transplanted
grafts (26). Many more cross-reactive T
cell responses may remain to be discov-
ered, including those that are based on
conformation rather than on sequence
similarity between peptide epitopes
(27). This task has suddenly become
much more difficult. As the paper by
Kim et al. (14) demonstrates, both clin-
ical and basic immunologists are now
faced with the difficulty of interpreting
individualized immune responses. Pri-
vate specificities of memory T cells ex-
ist not only in patients but also in in-
bred mice, and heterologous immunity
is determined by the unique private
specificities of these memory T cell
populations.
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